PRISM BioLab (206A) · TargetRestatedLatest Financial results briefing materials (2026-05-18): "Advanced"
Secure approximately 2 co-development agreements per year
First written in FY2024. 1 of 3 entries say "Restated". Latest entry: 2026-05-18.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
Continuous Acquisition of Co-Development ContractsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-05-18AdvancedFinancial results briefing materials
「Talus Bioscience • December 2025: Joint research agreement signed Receptor.AI • March 2026: Drug discovery partnership agreement signed」
The disclosure showed that a joint research agreement and a drug discovery partnership agreement had been signed with drug discovery biotechs, respectively. - FY2025RestatedAnnual report
「Going forward, we will target approximately 2 new contracts per year.」
The target of acquiring approximately 2 partnered development contracts per year continues to be stated. The number of contracted companies at fiscal year-end was 6 in Japan and overseas, although some contracts have ended. - FY2024First statedAnnual report
「Going forward, we will target approximately 2 new contracts per year.」
The company has set the number of new contracts acquired in its partnered development business as a target.